The EHD2 Knockout A2780 Polyclonal Cells provide a heterogeneous CRISPR/Cas9-edited population of A2780 ovarian carcinoma cells with targeted disruption of the EHD2 gene. This polyclonal format avoids clonal selection, delivering a pooled knockout model that minimizes artifacts from single-cell cloning. Researchers should confirm EHD2 protein depletion and functional pathway silencing prior to detailed studies.
A2780 is a cisplatin-sensitive human ovarian carcinoma epithelial cell line established from an untreated patient. Its epithelial phenotype, hormone receptor expression, and tumorigenicity make it a widely used system for ovarian cancer research, including chemosensitivity testing and metastasis studies. The A2780 genetic background provides a clinically relevant context for examining endocytic trafficking regulators in tumor progression.
EHD2 is an ATPase that associates with caveolae and controls the recycling of surface receptors, particularly integrin beta1. At caveolar sites, EHD2 interacts with caveolin-1, PACSIN2, and F-actin to promote the return of internalized integrins to the plasma membrane. Upstream regulation involves caveolin-1 and EGF stimulation, while downstream EHD2 modulates Rac1 GTPase activity, influencing focal adhesion kinase (FAK) signaling and actin cytoskeleton reorganization. Through these interactions, EHD2 facilitates focal adhesion turnover and suppresses cell migration, functioning as a metastasis suppressor. Key molecular partners include caveolin-1, annexin A2, and syndapin-2.
In ovarian carcinoma, EHD2 loss is predicted to enhance cell migration and invasion by disturbing integrin trafficking and Rac1 signaling. The A2780 EHD2 polyclonal knockout model enables dissection of these pathways in an epithelial cisplatin-sensitive system. Researchers can directly test how EHD2 deficiency alters adhesion dynamics and metastatic potential, and explore whether EHD2 status influences chemotherapeutic sensitivity, offering a platform for both basic and translational oncology research.
Key experimental approaches include transwell-based motility and invasion assays, immunofluorescence visualization of integrin beta1 and focal adhesion complexes, Western blot detection of EHD2, caveolin-1, and phospho-FAK, as well as Rac1 GTPase activation pull-downs, flow cytometric quantification of surface integrin levels, and extracellular matrix adhesion assays. Together these assays enable rigorous dissection of EHD2-dependent trafficking and signaling events. For additional information, please contact Ascent Research.
